TU Hai-yan. Safety and Activity, AZD9291 and Rociletinib in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(4): 208-209. DOI: 10.3969/j.issn.1671-5144.2015.04.004
|
Citation:
|
TU Hai-yan. Safety and Activity, AZD9291 and Rociletinib in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(4): 208-209. DOI: 10.3969/j.issn.1671-5144.2015.04.004
|
TU Hai-yan. Safety and Activity, AZD9291 and Rociletinib in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(4): 208-209. DOI: 10.3969/j.issn.1671-5144.2015.04.004
|
Citation:
|
TU Hai-yan. Safety and Activity, AZD9291 and Rociletinib in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2015, 15(4): 208-209. DOI: 10.3969/j.issn.1671-5144.2015.04.004
|
DownLoad: